Comparing the current results to its competitors, Nkgen Biotech Inc reported Revenue decrease in the 1 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 16.46 %, recorded in the same quarter.
Nkgen Biotech Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical, specialty pharmaceutical, biotechnology companies, academic research institutions, governmental agencies, and public and private research institutions globally. Competitors often possess greater financial resources and expertise in areas such as research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may further concentrate resources among fewer competitors. Smaller or early-stage companies may also present competition, either independently or in collaboration with larger entities.
Currently, the company faces competition from Acepodia, Artiva, Celularity, Century Therapeutics, Cytovia Therapeutics, Fate Therapeutics, Nkarta, and ImmunityBio, all of which have clinical-stage allogeneic programs. Additional competitors, including Affimed, Innate Pharma, Dragonfly Therapeutics, and GT Biopharma, are developing natural killer (NK) cell therapies utilizing cell engagers to direct patients' own NK cells to tumors. To date, the company is not aware of any other NK cell companies that have received FDA approvals for NK cell therapies.
March 3, 2025
Abstract: NKGen Biotech is at the forefront of developing innovative cellular therapies, including Troculeucel, which shows promise in treating post-stroke and Alzheimer’s disease (AD) patients. Recent advancements include the administration of Troculeucel to a stroke patient under an FDA-cleared compassionate use program and positive Phase 1 clinical trial results demonstrating improved cognitive outcomes in moderate Alzheimer’s patients. Additionally, data presented at the 2024 Alzheimer’s Association International Conference revealed that the SNK01 biomarker can effectively reduce levels of alpha-synuclein, a marker associated with cognitive decline in AD.NKGen Biotech has been actively exploring th...
June 12, 2024
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024SANTA ANA, Calif., June 12, 2024 - NKGen Biotech, a leading clinical-stage biotechnology company specializing in the development of innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, announced exciting updates during the 6th Annual Allogeneic Cell Therapies Summit. Led by Dr. Paul Y. Song, MD, Chairman, and CEO of NKGen, the presentation detailed the commercial manufacturing and cryopreservation process of the company s novel allogeneic blood-derived NK cell therapy, SNK02. Additionally, Dr. Song provided an update on the Pha...
May 20, 2024
Emerging Cell Therapy Shows Promise with No Adverse Drug-Related Events In recent developments heralding a potential breakthrough in Alzheimer s disease treatment, NKGen Biotech s SNK01, an autologous enhanced natural killer (NK) cell therapy, has received the green light to commence Phase 2 clinical trials. This follows promising results in preliminary studies where SNK01, a cryopreserved formulation delivered at its highest dose to date, demonstrated clinical benefits without any drug-related adverse events.Alzheimer s disease, a progressive neurodegenerative disorder characterized by cognitive decline and memory impairment, affects millions globally and remains a formidable challenge with limited therapeu...
April 18, 2024
Rejuvenating Hope: NKGen Biotech Presents Breakthrough SNK01 NK Cell Therapy for Neurodegenerative Diseases at Prestigious SummitSANTA ANA, Calif., April 18, 2024 - NKGen Biotech, Inc. (Nasdaq: NKGN) (NKGen or the Company), a leading clinical-stage biotechnology company specializing in innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, has recently unveiled exciting developments in the field of neurodegenerative disease treatment. With a focus on their revolutionary NK cell therapy, the company aims to revolutionize the way we approach conditions such as Alzheimer s and Parkinson s.At the upcoming 12th Annual Alzheimer s and Parkinson s Drug Development Summit, taking place ...
December 27, 2023
In a significant development, NKGen Biotech has recently announced the clearance of the clinical trial application by Health Canada for their groundbreaking SNK01 NK cell therapy, aimed at treating patients with moderate Alzheimer s disease. This achievement follows the FDA s IND clearance obtained by NKGens in October 2023, thereby augmenting the positive progress of the SNK01 program.Alzheimer s Disease: A Growing Healthcare Challenge:Alzheimer s disease, a degenerative neurological disorder, is becoming an increasingly prevalent global health challenge. It affects millions of individuals, causing cognitive decline, memory loss, behavioral changes, and ultimately leading to a loss of independence. Currentl...
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Century Therapeutics Inc. is a biotechnology company that aims to develop novel cell therapies targeting various diseases. Their business model focuses on leveraging induced pluripotent stem cell (iPSC) technology to engineer cellular therapies and bring them to market, with a specific emphasis on treating cancer.
Sources:
Nkgen Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nkgen Biotech Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
